Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- cohort label "Adults" assertion.
- association label "The most commonly reported diagnosis treated was Major Depressive Disorder (72.2%), followed by Bipolar Disorder (15.1%), and Posttraumatic Stress Disorder (5.7%). Most providers (87.7%) reported administering ketamine via an intravenous route, with a minority reporting using an oral (22.8%) or an intranasal (19.3%) formulation." assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol depedence" assertion.
- MONDO_0007079 label "alcohol dependence" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants.It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- cohort label "Adults" assertion.
- association label "nly a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- association label "Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns). Efficacy outcomes also differed between agents used as adjunctive therapy (OR, 1.39; 95% CI, 1.19-1.64) or monotherapy (OR, 2.25; 95% CI, 0.67-7.52)." assertion.
- cohort label "Adults" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "major depressive disorder" assertion.
- MONDO_0002009 label "Major depressive disorder" assertion.
- MONDO_0002009 label "Major depressive disorder" assertion.
- MONDO_0002009 label "Major depressive disorder" assertion.
- MONDO_0002009 label "Major depressive disorder" assertion.
- cohort label "Adults" assertion.
- association label "Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns)." assertion.
- association label "Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns)." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "First-line options include Modafinil/Armodafinil (for excessive daytime sleepiness, EDS), Sodium Oxybate (for EDS and/with cataplexy), Pitolisant (for EDS and cataplexy) and Venlafaxine (for cataplexy (off-label) and co-morbid depression)." assertion.
- HP_0002524 label "Cataplexy" assertion.
- HP_0002524 label "Cataplexy" assertion.
- HP_0002524 label "Cataplexy" assertion.
- HP_0002524 label "Cataplexy" assertion.
- cohort label "Elderly" assertion.
- association label "Prescriptions for five oral SGAs (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) were reviewed, and veterans were considered to be users if they received a minimum of one 30-day outpatient prescription for any dose or 3 consecutive days of inpatient administration (continuation at discharge was not required) in the 6 months after the index date." assertion.
- association label "Prescriptions for five oral SGAs (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) were reviewed, and veterans were considered to be users if they received a minimum of one 30-day outpatient prescription for any dose or 3 consecutive days of inpatient administration (continuation at discharge was not required) in the 6 months after the index date." assertion.
- cohort label "Elderly" assertion.
- cohort label "Adults" assertion.
- association label "Amitriptyline also has different off-label uses, including migraine prevention, neuropathic pain management, fibromyalgia, and enuresis (bedwetting)" assertion.
- cohort label "Adults" assertion.
- association label "Amitriptyline also has different off-label uses, including migraine prevention, neuropathic pain management, fibromyalgia, and enuresis (bedwetting)." assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- step label "awesome smoothening of an image" assertion.
- association label "Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment." assertion.
- cohort label "Adults" assertion.
- MONDO_0005052 label "Irritable bowel syndrome" assertion.
- MONDO_0005052 label "Irritable bowel syndrome" assertion.
- MONDO_0005052 label "irritable bowel syndrome" assertion.
- cohort label "Adults" assertion.
- association label "Off-label use • Imipramine • Bupropion • Modafinil" assertion.
- association label "Haloperidol can also be used to treat behavioral disorders and hyperactivity, and it is sometimes used off-label for nausea and vomiting (from chemotherapy, advanced or terminal illness, and surgery), chorea (jerky, involuntary movements) associated with Huntington disease, treatment and prevention of delirium in the intensive care unit, obsessive- compulsive disorder (OCD), phencyclidine-induced psychosis, psychosis/agitation associated with dementia, and rapid control of agitation, aggression, and violent behavior" assertion.
- cohort label "Adults" assertion.
- association label "Haloperidol can also be used to treat behavioral disorders and hyperactivity, and it is sometimes used off-label for nausea and vomiting (from chemotherapy, advanced or terminal illness, and surgery), chorea (jerky, involuntary movements) associated with Huntington disease, treatment and prevention of delirium in the intensive care unit, obsessive- compulsive disorder (OCD), phencyclidine-induced psychosis, psychosis/agitation associated with dementia, and rapid control of agitation, aggression, and violent behavior" assertion.
- cohort label "Adults" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "obsessive-compulsive disorder" assertion.
- MONDO_0008114 label "Obsessive Compulsive Disorder" assertion.
- MONDO_0008114 label "obsessive compulsive disorder" assertion.
- MONDO_0008114 label "obsessive compulsive disorder" assertion.
- MONDO_0008114 label "obsessive compulsive disorder" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- MONDO_0001627 label "dementia (disease)" assertion.
- spi label "the protein TDP-43 represses cryptic exon inclusion in the gene UNC13A" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Antipsychotics have been found to reduce BPD symptoms including aripiprazole (mean daily dose: 15 mg); ziprasidone (mean daily dose: 20 to 80 mg), olanzapine (mean daily dose: 5 to 9 mg, daily dose range 5 to 20 mg), haloperidol (mean daily dose 5 mg, daily dose range 4 to 16 mg), Quetiapine XL (at a daily dose of 150 mg)." assertion.
- cohort label "Adults" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.